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Abstract
Background: Phelan-McDermid syndrome (PMS) is a genetic condition characterized by intellectual disability,
speech and language deficits, hypotonia, autism spectrum disorder, and epilepsy. PMS is caused by 22q13.33
deletions or mutations affecting SHANK3, which codes for a critical scaffolding protein in excitatory synapses.
SHANK3 variants are also known to be associated with an increased risk for regression, as well as for psychiatric
disorders, including bipolar disorder and catatonia. This study aimed to further describe these phenomena in PMS
and to explore any relationship between psychiatric illness and regression after early childhood.
Methods: Thirty-eight people with PMS were recruited to this study through the Phelan-McDermid Syndrome
Foundation based on caregiver report of distinct development of psychiatric symptoms. Caregivers completed a
clinician-administered semi-structured interview focused on eliciting psychiatric symptomatology. Data from the
PMS International Registry were used to confirm genetic diagnoses of participants and to provide a larger sample
for comparison.
Results: The mean age of the 38 participants was 24.7 years (range = 13 to 50; SD = 10.06). Females (31 of 38 cases;
82%) and sequence variants (15 of 38 cases; 39%) were over-represented in this sample, compared to base rates in
the PMS International Registry. Onset of psychiatric symptoms occurred at a mean age of 15.4 years (range = 7 to
32), with presentations marked by prominent disturbances of mood. Enduring substantial loss of functional skills
after onset of psychiatric changes was seen in 25 cases (66%). Symptomst indicative of catatonia occurred in 20
cases (53%). Triggers included infections, changes in hormonal status, and stressful life events.
Conclusions: This study confirms that individuals with PMS are at risk of developing severe neuropsychiatric illness
in adolescence or early adulthood, including bipolar disorder, catatonia, and lasting regression of skills. These
findings should increase the awareness of these phenotypes and lead to earlier diagnosis and the implementation
of appropriate interventions. Our findings also highlight the importance of genetic testing in the work-up of
individuals with intellectual disability and acute psychiatric illness or regression. Future research is needed to clarify
the prevalence and nature of psychiatric disorders and regression among larger unbiased samples of individuals
with PMS.
Keywords: Phelan-McDermid syndrome, SHANK3, Mania, Depression, Bipolar disorder, Psychosis, Catatonia,
Regression
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Background
Phelan-McDermid syndrome (PMS) is a neurogenetic
syndrome caused by haploinsufficiency of the SHANK3
gene due to a spectrum of anomalies in the terminal re-
gion of the long arm of chromosome 22, ranging from
single-nucleotide variants to large deletions affecting
multiple genes [1]. SHANK3 is a key structural protein
in excitatory synapses, with several isoforms with differ-
ent functions in development and in the synapse [2, 3].
Deletions or sequence variants of the SHANK3 gene are
associated with the neuropsychiatric manifestations of
the syndrome and required for the diagnosis of PMS [4–
7]. Individuals with PMS often present with intellectual
disability (ID), features of autism spectrum disorder
(ASD), hypotonia, and severely delayed or absent speech
[8–10]. Genotype-phenotype studies in individuals with
terminal deletions have found that the severity of speech
impairment and intellectual disability increases with in-
creasing deletion size [8, 9]. In one recent study examin-
ing phenotypic manifestations among 17 individuals
with sequence variants within SHANK3 [7], the majority
developed single words, and 44% had phrase speech, in
contrast to more severe impairment in individuals with
deletions.
Epilepsy is reported in 17% to 70% of individuals with
PMS [9, 11–14]. As individuals with PMS age, they ap-
pear to be at increased risk for bipolar disorder [15–20]
and an associated risk of significant cognitive and behav-
ioral regression [5, 6, 16, 18–20]. Indeed, SHANK3 vari-
ants have been implicated in the risk for severe
neuropsychiatric disorders, including mood and psych-
otic disorders [15, 16, 19, 21, 22]. Gauthier et al. (2010)
identified sequence variants in the SHANK3 gene in four
individuals initially diagnosed with atypical, early-onset
schizophrenia, and a history of borderline to mild intel-
lectual disability [21]. Catatonia, a unique syndrome of
motor and autonomic dysregulation associated with a
variety of psychiatric and medical conditions, has also
been described in PMS [7, 15, 22, 23]. Of note, catatonia
in pediatric populations and in individuals with develop-
mental disabilities often goes unrecognized [24] and
poorly treated [25].
A few previous cross-sectional studies have used sys-
tematic methods to characterize the behavioral profile of
individuals with PMS across the lifespan [19, 26–28].
However, the nature and course of psychiatric symptoms
in PMS, and in particular their association with regres-
sion occurring much later than the early childhood re-
gressions typical of ASD, have not been extensively
documented. In this retrospective study, we collected de-
velopmental histories, behavioral profiles, and genetic
findings of 38 adolescents and adults with PMS and psy-
chiatric illness with the aim to (1) better characterize the
psychiatric and developmental phenomena reported in
PMS and (2) aid in early recognition and treatment
optimization.
Methods
Participants and procedures
The study was approved by the Institutional Review
Board of the PMS International Registry (PMSIR)
(https://www.pmsf.org/registry/). Informed consent for
participation in the Registry was obtained from the par-
ents or legal guardians of participants, who also signed a
release for inclusion in publication, and for integration
of their interview data with their PMSIR data. Families
were recruited by outreach through the PMS Foundation
community Facebook page, and families were specifically
invited to participate if the individual with PMS had ex-
perienced distinct psychiatric changes, such as mood ep-
isodes, psychosis, marked changes in sleep and energy,
major loss of skills, sudden new intense obsessive-
compulsive behaviors, or other neuropsychiatric difficul-
ties, with or without regression. Families either con-
tacted the researcher (TMK) directly in response to the
Facebook message or responded after other families
relayed the recruitment message on Facebook to parents
with possible clinical concerns as described. In addition
to the 37 English-speaking families, six families were re-
ferred through the PMS Spanish Association, and two
enrolled and completed the study procedures.
Thirty-seven caregivers completed interviews on 39
participants and provided informed consent; one partici-
pant was excluded from the analysis since criteria were
not met for a distinct psychiatric episode. Three families
had responded to the invitation but did not complete in-
terviews or consent after an initial contact established
that they did not meet criteria for a distinct psychiatric
episode. The final sample included 38 individuals from
36 families, ranging in age from 13 to 50 at the time of
contact. The sample includes two sets of monozygotic
twins with both twins enrolled. Caregivers interviewed
were mothers in all but one case, in which the respond-
ent was a sibling who was the legal guardian. Interviews
were conducted in English (n = 34) or Spanish (n = 2),
and respondents lived in the USA (n = 29), Australia
(n = 4), Canada (n = 1), England (n = 1), Netherlands
(n = 1), and Spain (n = 2).
Measures
A semi-structured interview entitled the Caregiver Inter-
view for Psychiatric Illness in Persons with ID (see Add-
itional file 1) was developed by TMK and conducted
with caregivers by child and adolescent psychiatrists
(TMK for English interviews and MPT for Spanish inter-
views). The interview includes questions designed to
elicit descriptions of the participant’s developmental his-
tory, major health challenges, the emergence and course
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of episodes of psychiatric illness or regression, response
to pharmacologic treatment, and current level of func-
tioning. Interviews typically lasted 90 min. All final notes
were reviewed and approved by the families before in-
clusion in the study.
Genetic reports were obtained for all participants and
reviewed by the geneticist (CB) curating results for the
PMSIR. PMSIR data were used to confirm genetic re-
sults for study participants and for comparisons of
prevalence of genetic variants, age, and gender. However,
only 21 of 38 participants in this study had completed
the PMSIR clinical and developmental questionnaires,
limiting direct comparisons of clinical data between
study participants and other Registry members. Nine of
38 participants were not enrolled in the Registry prior to
study participation.
Comparisons between functional status and develop-
mental milestones in study participants vs Registry data
included parent report of whether key developmental
skills were ever achieved on the Caregiver Interview (for
the study sample) and on the Registry’s Developmental
Questionnaire for a group of respondents of similar age,
with Registry data excluding the participants who were
enrolled in the current study.
Assessment of behavioral symptoms and labeling of
psychiatric diagnoses in the context of neurodevelop-
mental disorders is complicated by cognitive and com-
municative limitations, atypical presenting features, and
premorbid characteristics (e.g., echolalia, repetitive be-
haviors). The Diagnostic and Statistical Manual for Men-
tal Disorders, 5th edition [29] does not comprehensively
include modifications of all diagnostic criteria for differ-
ential manifestations that may present in the context of
intellectual disability, and there is a dearth of psycho-
metrically rigorous instruments validated for psychiatric
evaluation in this population. Therefore, we used the
Diagnostic Manual - Intellectual Disability, Second Edi-
tion (DM-ID-2) [30] to classify psychiatric episodes. The
DM-ID-2 is based on the DSM, adapted to include care-
giver observations of behavior and to reduce the number
of symptoms required to make diagnoses where persons
with intellectual disability may not be able to report ex-
periences [31]. All cases were reviewed by a child and
adolescent psychiatrist (TMK) using a checklist of DM-
ID-2 criteria for each of these disorders. The symptoms
reported by caregivers during acute episodes met criteria
for major depressive episode, manic episode, obsessive-
compulsive disorder, generalized anxiety disorder, brief
psychotic disorder, schizoaffective disorder, and catato-
nia associated with another mental disorder (see Add-
itional file 2). In addition, two child and adolescent
psychiatrists (MPT, AK) randomly reviewed and classi-
fied eight cases to assure accuracy of diagnostic classifi-
cation. Agreement on the presence of a mood disorder
was 100%, agreement on whether the first mood episode
was depressive or manic was 88%, and agreement on the
presence of catatonia was 88%.
The word “regression” is often used to describe a wide
variety of states, including transient loss of skills during
psychiatric episodes with and without catatonia. For
clarity, “regression” was defined in this study as a pro-
longed loss of previously acquired skills that either (a)
began when the individual was psychiatrically well or (b)
began during a psychiatric episode, with loss of skills
persisting for at least 6 months beyond the resolution of
the psychiatric episode.
Results
Descriptive statistics and comparisons to participants in
the PMSIR are reported in Table 1. Summaries of case
histories and genetic findings are reported in Table 2.
There was a strong female predominance in this sample
(31 females, 7 males) whereas PMS typically affects
males and females in equal proportion. There were 23
individuals with terminal deletions, with a mean size of
1.63Mb (range 160 kb–6.41Mb). Five deletions were
secondary to a chromosomal rearrangement: a ring
chromosome 22 in three individuals and an unbalanced
translocation in two. Twelve individuals with terminal
deletions had not had a karyotype, so the possibility of a
ring chromosome 22 cannot be excluded. Fifteen indi-
viduals had pathogenic sequence variants in SHANK3
(12 frameshift variants and 3 nonsense variants).
As compared with the 509 PMSIR registrants not in
this study who had genetic data available, sequence vari-
ants in SHANK3 were present at higher rates in our
sample (39% [15/38] vs 6% [32/509]; Fisher’s exact test,
p = 4 × 10− 8), and conversely, terminal deletions were
less frequent (61% [23/38] vs 92% [467/509]; Fisher’s
exact test, p = 8 × 10− 7). Comparisons with 130 PMSIR
registrants of similar age with questionnaire data avail-
able are also reported in Table 1. In addition, deletions
tended to be smaller in the participants of this study
than in the PMSIR (mean size 1.634Mb vs 3.633Mb;
unpaired two-tailed Student’s t test, p = 0.0019). In par-
ticular, individuals with small deletions, defined as those
including at most the four distal genes, ARSA, SHANK3,
ACR, and RABL2B, are over-represented among study
participants compared to the PMSIR (57% [12/21 dele-
tions with size information] vs 19% [72 /387]; Fisher’s
exact test, p = 1.6 × 10− 4). (Heterozygous loss of ARSA,
ACR, and RABL2B does not contribute to the PMS
phenotype, so deletions including these genes are
equivalent to deletions involving only SHANK3.)
Developmental history
Although documentation of the severity of ID was not
available, reported levels of adaptive functioning suggest
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that mild to moderate ID was common in this sample
prior to the onset of psychiatric symptoms and regres-
sion and that these individuals were less impaired prior
to their psychiatric illness as compared to the PMSIR
reference sample (Table 1). Prior to the onset of psychi-
atric illness, study participants were significantly more
likely than participants in the PMSIR sample to ever
have walked independently, achieved toilet training, ver-
bal expression with at least phrase speech, and inde-
pendence with dressing.
Psychiatric illness
Psychiatric difficulties began between ages 10 and 18 in
the majority of cases (28/38; 74%). Psychiatric symptoms
emerged between the ages of 7 and 10 years in 5/38
cases (13%), while 5/38 cases (13%) developed psychi-
atric symptoms between ages 21 and 32. Using the DM-
ID-2, first episodes met criteria for a manic episode in
17/38 cases (45%) and for a depressive episode in 14/38
cases (37%). First episodes in the remaining cases in-
cluded six (16%) with a mixture of mood and anxiety
symptoms, and one case of disorganized, bizarre behav-
ior that suggested a brief psychotic episode.
Most participants (27/38; 71%) had experienced a
mood episode in the year before the study. The after-
math of acute episodes was associated with higher base-
line levels of anxiety and irritability and with regression.
Subsequent psychiatric episodes were superimposed and
caregivers clearly distinguished episodes from baseline
states. First episodes ranged from 8months to 35 years
before study participation. Reported episode length var-
ied from periods of days to months. Most cases (34/38;
89%) had multiple distinct episodes consistent with a
mood disorder, including 12 of 38 (32%) with two to
four distinct episodes, 6 of 38 (16%) with five to nine ep-
isodes, and 16 of 38 (42%) with more than ten episodes
(see Table 2 for details). Few cases (4/38; 11%) reported
only a single psychiatric episode; all four of these were
within the 3 years prior to study participation.
Twenty-nine of 38 cases (76%) reported a manic epi-
sode at some point in their illness; 24 of 38 (63%) re-
ported both manic and depressive episodes. Nineteen of
38 cases (50%) were reported to have had psychotic
symptoms during an acute mood episode. One partici-
pant presented with both depressive and manic episodes
and with psychosis in between mood episodes, suggest-
ing schizoaffective disorder.
New anxiety symptoms accompanied mood episodes
in the majority of participants (26/38; 68%). Six partici-
pants (16%) met criteria for obsessive-compulsive dis-
order at some point in the course of their illness. Four
participants (11%) met criteria for generalized anxiety
disorder. Only two participants (5%) had first episodes
that were predominantly anxious.
Table 1 Demographic and clinical variables in the study sample as compared to the Phelan-McDermid Syndrome International
Registry (PMSIR) participants 13 or older
This study (n = 38) PMSIR (n = 130) Comparison
Mean age at data collection 24.7 years ± 9.92 20.8 years ± 7.65 t(166) = 2.56, p = .011
χ2(1) = 10.21, p = .001
Gender
Male 18% (7/38) 47% (61/130) χ2(1) = 10.20, p = .001
Female 82% (31/38) 53% (69/130)
Genetic defect a
Terminal deletion 61% (23/38) 91% (118/130) χ2(1) = 19.79, p < .001
Interstitial deletion – 2% (3/130)
SHANK3 sequence variant 39% (15/38) 7% (9/130)
ASD diagnosis (ever)d 55% (21/38) 41% (37/91b) χ2(1) = 2.105, p = .147
History afebrile seizure(s) 39% (15/38) 41% (37/91) χ2(1) = .044, p = .834
Walked independently (ever) 100% (38/38) 81% (64/79c) χ2(1) = 8.212, p = .004
Spoke in phrases or sentences (ever) 79% (30/38) 51% (40/79) χ2(1) = 8.317, p = .004
Toileted independently “always” or “sometimes” (ever) 89% (34/38) 48% (38/79) χ2(1) = 18.029, p < .001
Dressed self independently (ever) 78% (30/38) 42% (33/79) χ2(1) = 13.26, p < .001
Chronic constipation 84% (32/38) 15% (14/91) χ2(1) = 55.428, p = <.001
Acute urinary retention 47% (18/38) 3% (3/87) χ2(1) = 37.091, p < .001
aAmong all Registry participants (n = 509, excluding the study participants), there are 467 terminal deletions (92%), 10 interstitial deletions (2%) and 32 sequence
variants (6%)
b91 participants in this age range (excluding the study participants) completed the Registry Clinical Questionnaire
c79 participants in this age range (excluding the study participants) completed the Registry Developmental Questionnaire
dPrior to the onset of neuropsychiatric illness, 42% (16/38) of participants had ASD diagnoses
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Symptoms consistent with a diagnosis of catatonia as-
sociated with another mental disorder were reported in
20 of 38 cases (53%). Seven of the 20 (35%) were on neu-
roleptics at the time of emergence of catatonic symp-
toms. Cases with sequence variants in SHANK3 met
diagnostic criteria for catatonia significantly more often
(12/15; 80%) than cases with terminal deletions (8/23;
35%) (Fisher’s exact test, p = 0.009).
Regression
The interview explored both abilities lost and the degree
of return of skills over time. Caregivers were asked
which skills were lost, at what age, and which, if any,
skills were regained. Seven of the participants (18%) had
experienced regressions in early childhood affecting
communication, social interaction, and/or imaginative
play (five by age two, one at age four, one at age seven),
but we do not elaborate on those early regressions in the
current report. Analysis focused on the 25 of 38 cases
(66%) who had regressions that began within the 3 years
after the onset of psychiatric episodes. Most of these re-
gressions (21/25; 84%) began within a year after the on-
set of psychiatric episodes and involved multiple
domains of function. Descriptions of the areas of skill
lost and recovery are summarized in Table 2, which in-
cludes developmental status in terms of speech, toilet
training, ability to dress and wash self, academic skills,
and vocational activities when present. Caregiver reports
of recovery of skills ranged from continuing loss of fur-
ther skills to complete return to baseline function before
the onset of psychiatric symptoms. Overall, more than
half of the participants who regressed in the 3 years after
the onset of psychiatric illness reported minimal recov-
ery (14/25; 56%).
Antecedents to the onset of psychiatric illness and re-
gression were explored in the interview. Menstrual cyc-
ling was reported to play a triggering role in 11 of 31
(35%) of the females. Acute infections were suspected
triggers in 11 of 38 cases (29%). Psychosocial stressors
were suspected triggers in 10 of 38 cases (26%). Several
participants reported differing antecedent stressors for
different episodes.
Co-morbid conditions
Only a quarter (9/38; 24%) of study participants was
known to have PMS before the onset of psychiatric symp-
toms and associated regression. Sixteen cases (42%) had
diagnoses of ASD before the onset of psychiatric symp-
toms and regression; five more received an ASD diagnosis
after the onset of psychiatric illness and regression.
Fifteen of 38 cases (40%) reported one or more
afebrile seizure. Eight of those 15 cases (53%) re-
ported a seizure in the 2 years preceding the inter-
view. Fifteen of 38 cases (40%) had weight loss of 10
to 25 kg accompanying psychiatric episodes. Chronic con-
stipation, intermittent urinary incontinence, and episodes
of acute urinary retention were prevalent in this sample,
particularly as subjects aged. Chronic constipation was
noted in 32 cases (84%), with episodes of acute urinary re-
tention reported in 18 (47%). The discomfort associated
with these conditions may lead to non-specific behaviors
such as agitation, aggression, and self-injury in people with
ID; these chronic symptoms were not coded as mood epi-
sodes. A small subset of subjects (4/38; 11%) had an
immune-related disorder. Two participants (5%) were di-
agnosed with Hashimoto’s thyroiditis, one of whom was
diagnosed with Hashimoto’s encephalopathy, and two par-
ticipants (5%) had immunoglobulin deficiency, including
one with common variable immunodeficiency.
Therapeutic interventions
At the time of interview, 32 of 38 participants (84%)
were receiving one or more psychiatric medications,
with 14 of 38 (37%) receiving four or more psychi-
atric medications. More than half (21/38; 55%) took
anticonvulsants; all of these had mood symptoms,
while 12 also had a history of seizures. Over half
(55%) were receiving neuroleptics. Benzodiazepines
were used either regularly or on an as-needed basis
in 16 of 38 cases (42%). Alpha agonists, beta-blockers,
antihistamines, and trazodone were prescribed for
sleep or aggression. Smaller numbers of participants
were receiving selective serotonin reuptake inhibitors
(SSRIs), tricyclic antidepressants, buspirone, lithium,
cannabinoid oil, or n-acetylcysteine.
Full details of dosages and adjustments to treatment
regimens in response to changing psychiatric status
were inconsistently available and are therefore not re-
ported. However, many parents kept extensive notes,
and their reports of responses to medication trials
suggest two patterns worth noting: (1) participants
were reported to be sensitive to side effects from neu-
roleptics, with adverse events including extrapyramidal
symptoms, worsening aggression and/or onset of cata-
tonic symptoms reported in 14 of 30 cases (47%),
while (2) seven of nine participants (78%) treated with
SSRIs for depressive symptoms developed agitation,
aggression, or other manic-like symptoms within
weeks of the start of treatment.
Three individuals were treated with electroconvulsive
therapy (ECT) for catatonia with reported significant
benefit; two continue to require maintenance ECT (dur-
ation of treatment 18 months in one, > 8 years in the
other) while the third discontinued after initial response
due to agitation. One participant with recurrent catato-
nia on maintenance ECT was reported to have also
benefited from intravenous immunoglobulin (IVIG) with
improved cognition and motivation, but developed
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aseptic meningitis and a rash after the fifth treatment,
leading to discontinuation of IVIG.
Nine participants (26%) were reported to have received
immunomodulatory treatments for diagnoses of
pediatric autoimmune neuropsychiatric disorders associ-
ated with streptococcal infections (PANDAS) syndrome
or of autoimmune encephalopathy. Six were diagnosed
with PANDAS syndrome on the basis of clinical symp-
toms and positive strep cultures or elevated titers. One
participant was diagnosed with Hashimoto’s encephalop-
athy, and two with seronegative autoimmune encephal-
itis. Treatments included (1) antibiotics, (2) IVIG, and/
or (3) systemic anti-inflammatories such as nonsteroidal
anti-inflammatory drugs, steroids, or rituximab.
In four of six cases diagnosed with PANDAS syn-
drome, parents reported that antibiotic treatment was
effective in reducing or eliminating acute symptoms.
The remaining two improved slowly; one also re-
ceived IVIG and the other received lorazepam; these
parents were not confident that antibiotics had played
a role in recovery. Treatment for PANDAS symptoms
did not appear to prevent future mood episodes or
regression, as all but one of these cases went on to
have further psychiatric episodes and some had later
regressions. The one participant diagnosed with
Hashimoto’s encephalopathy continues to receive
regular infusions of IVIG with steroids, as well as
rituximab. The two participants with diagnoses of
seronegative autoimmune encephalopathy receive
monthly IVIG.
Eight females were on hormonal therapy to eliminate
menstrual cycles and reduce associated mood symptoms.
Non-pharmacological treatments varied widely by geo-
graphic location and age, with those still in school more
likely to be receiving structured behavioral interventions.
Data on past and current behavioral programs and ther-
apies were not included in the interview.
Discussion
This case series has characterized a subset of individuals
with PMS who have episodic, severe neuropsychiatric ill-
ness, frequently beginning in adolescence or early adult-
hood, with major impacts on functional status. The
symptoms and course of illness often closely resembled
bipolar illness, with psychotic features almost exclusively
present in the context of mood episodes. None of the
participants in our sample presented with a primary
psychotic disorder, such as schizophrenia. However, one
participant presented with distinct psychotic and
affective episodes characteristic of schizoaffective dis-
order. Using the DM-ID-2 criteria [30], all but one of
the participants had either a mood disorder or an anx-
iety disorder, with multiple discrete periods of illness in
all but four.
Several triggers were often reported as temporal ante-
cedents to the onset of psychiatric changes. Biological
triggers included infections and changes in hormonal
status, while environmental factors included stressful life
events. Similar patterns have been observed in other,
more common neurogenetic syndromes, including Down
syndrome [32], Williams syndrome [33], and 22q11.2 de-
letion syndrome [34].
It is critical to emphasize the high incidence of catatonic
symptoms in this subset of individuals with PMS, as cata-
tonia often goes unrecognized or undertreated in individ-
uals with developmental disabilities [25, 35]. Recognition
and treatment of both stuporous and hypermotoric cata-
tonia is crucial, as symptoms can lead to life-threatening
complications. Other genetic conditions involving copy
number variants, such as 22q11.2 deletions [36], have also
been associated with psychiatric symptoms and with cata-
tonia. Similar to their use in treating catatonia in other
conditions, benzodiazepines and ECT were used in this
cohort with reported tolerability and effectiveness.
Regression has long been recognized in neurodevelop-
mental disorders such as ASD [37], but the triggers and
mechanisms are not well understood, and the literature
focuses largely on early childhood regression, especially
as it relates to Rett syndrome [37–40]. Significant cogni-
tive and behavioral regression has been documented in
PMS [5, 6, 9, 15, 16, 18, 41]. Verhoeven et al. [20] have
recently published on the course of illness of 24 adoles-
cents and adults with PMS referred for evaluation and
treatment of “challenging behaviors and unstable mood.”
In that sample, there were five individuals with periodic
catatonic symptoms, and four other individuals who de-
veloped progressive loss of skills in their third or fourth
decade.
Two thirds (66%) of our sample described lasting regres-
sions that began within 3 years of the onset of psychiatric
illness. These regressions in communication, self-care, and
motor functions left a subset of previously more capable
individuals largely non-verbal, incontinent, and unable to
dress or feed themselves. Many of these participants con-
tinue to experience episodic psychiatric illness in addition
to developmental decline. Interestingly, a similar combin-
ation of rapid onset psychiatric disturbance with marked
regression and catatonia has been described in Down syn-
drome [42, 43] and subsequently labeled “Down syndrome
disintegrative disorder.” A recent case series [44] docu-
mented a role for immunotherapy in restoring function
and stability in these individuals, although it is also recog-
nized that cognitive decline in Down syndrome relates to
amyloid precursor protein gene triplication [45–47]. Re-
gression in PMS may be more common than in Down
syndrome, and its potentially devastating impact warrants
ongoing study of the natural history, mechanism, and tar-
gets for intervention.
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Given the methodological limitations and sample se-
lection bias in this study, we are unable to draw conclu-
sions about the prevalence of psychiatric illness and/or
regression among people with PMS. This study was also
limited by the lack of standardized or validated tools to
measure neuropsychiatric symptoms in severely develop-
mentally disabled children and adults. However, within
this self-referred subset of individuals with PMS whose
caregivers identified psychiatric illness, we observed a
distinct pattern of affective episodes, with onset typically
in puberty, a strikingly high incidence of catatonic symp-
toms, and an association with substantial regression in
the second through fourth decades of life. Of note, a re-
cent literature review analyzed prior reports of 56 indi-
viduals with PMS with accompanying neuropsychiatric
symptoms, and concluded that “clinicians and caregivers
need to be vigilant for loss of skills and neuropsychiatric
changes in adolescents and adults with PMS, including
the development of bipolar disorder and catatonia” [48].
Individuals with PMS who present with new psychiatric
symptoms require careful monitoring and cautious early
intervention. Response to traditional psychiatric interven-
tions is variable, and the role for immunomodulatory
treatments and ECT in specific subsets of patients should
be explored in future studies. The pattern of rapid and se-
vere deterioration described in more than half of this
group calls for further investigation to identify triggers
and the underlying biology and to delineate possible strat-
egies for prevention and timely intervention. While the
current study does not allow for specific treatment recom-
mendations, there is an urgent need for clinical trials to
assess the efficacy of existing psychopharmacological
treatments for psychiatric symptoms in PMS, in addition
to developing novel, targeted therapeutics.
The preponderance of females in this sample (> 4:1) is
notable and calls for replication. Sequence variants in
SHANK3 were also six times more common in this sam-
ple than in the PMSIR. These findings raise questions
about whether psychiatric problems and regression dis-
proportionately affect females and/or individuals with
SHANK3 sequence variants, in contrast to those with de-
letions. In addition, prior to the onset of psychiatric ill-
ness, most of the participants described herein were less
severely impaired in their adaptive functioning than is
reported in most studies of PMS. This finding is likely
related to the high proportion of individuals with
SHANK3 variants and small deletions in this sample.
Further studies should attempt to clarify if psychiatric
difficulties are actually more common in individuals who
are more verbal and social and who have more intact
adaptive functioning at baseline, or, whether this finding
is the result of selection bias in our sample, as the ma-
jority of participants (76%) were only diagnosed with
PMS after the onset of psychiatric symptoms.
Finally, our sample underscores the importance of
genetic testing as part of the medical work-up for indi-
viduals with this presentation. Chromosomal microarray
is recommended for the evaluation of all children with
global developmental delay or intellectual disability [49].
In the setting of superimposed psychiatric illness or re-
gression, chromosomal microarray should be considered
as first tier testing, followed by sequencing of SHANK3
if the microarray is unrevealing.
Conclusion
This study confirms that individuals with PMS are at
risk of developing severe neuropsychiatric illness in ado-
lescence or early adulthood. In most cases, the symp-
toms appear consistent with the expression of bipolar
disorder in individuals with intellectual disability, with
catatonia noted as a common co-occurring condition.
Triggers may include infections, changes in hormonal
status, and stressful life events. Significant cognitive and
behavioral regression beyond a baseline level of disability
has been previously reported in PMS and accompanied
the onset of psychiatric illness in a majority of the cases
reported here. Our results must be interpreted with cau-
tion given the potential selection bias in recruitment,
but it is clear that people with PMS may show a rapid
and severe deterioration that requires careful monitoring
and intervention. Our findings also highlight the rele-
vance of genetic testing in the work-up of individuals
with intellectual disability and acute psychiatric illness
or regression. Future research is needed to clarify the
prevalence and nature of psychiatric symptoms and re-
gression among larger unbiased samples of individuals
with PMS and to delineate any shared mechanisms with
other neurodevelopmental disorders presenting with
psychiatric illness and/or regression in adolescence or
early adulthood. Identification of early clinical and bio-
logical markers would contribute to our understanding
of the underlying neurobiology of these disorders and
potentially aid in monitoring, early intervention, or
prevention.
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